Telomir Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) on June 21, 2024, covering events that occurred on June 18, 2024. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation arrangements:
- Separation Payment: $62,500 total to be paid to the departing CFO in equal installments over three months.
- New CFO Salary: $137,500 annual base salary for the newly appointed CFO.
- Equity: The new CFO will not receive equity compensation in connection with the appointment.
Material Changes
The primary material change reported is the transition of the Chief Financial Officer role:
- Resignation: Nathan Fuentes resigned as Chief Financial Officer effective June 18, 2024. The resignation was mutual and not based on any disagreement regarding company operations or policies.
- Appointment: Michelle Yanez, MBA, was appointed as the new Chief Financial Officer effective June 18, 2024. Ms. Yanez had previously served as the company's part-time Corporate Controller since May 2022.
Outlook, Risks, and Management Commentary
Management commentary focuses on the qualifications of the new CFO and the terms of the transition. Ms. Yanez brings over 25 years of experience in the biotech and pharmaceutical sectors, including roles as CFO at MIRA Pharmaceuticals and various leadership positions at BioDelivery Sciences International. The filing notes that the new employment agreement includes a sign-on bonus related to a Change of Control and eligibility for discretionary annual and long-term incentive bonuses. No specific risks, contingencies, or unusual items beyond the leadership change are disclosed in this report.
Investor Verification Checklist
- Verify the terms of the Confidential Separation and Mutual General Release Agreement with Nathan Fuentes.
- Review the full text of the CFO Employment Agreement with Michelle Yanez (Exhibit 10.1) for details on the sign-on bonus and performance objectives.
- Confirm the impact of the CFO transition on the company's ongoing financial reporting and audit processes.
- Check for any subsequent filings regarding the "Change of Control" mentioned in the new CFO's compensation package.